



Digital

Transforming Lives with Digital Medicines

Data for Secondary Uses

April 2022

Presented by:

Steve Marks
Medicine Data for Secondary Uses Workstream
Part of the Digital and Interoperable Medicines Programme - NHS Digital
medsdata@nhs.net



Objectives of the drop in session



1. **Why** are we trying to collect data from ePMA systems?



2. **What** data are we proposing to collect from ePMA systems?



3. **When** are we proposing to collect and the timescales?



4. **Feedback**, thoughts and questions?

Why are we trying to collect ePMA data

Only limited patient-level medicine data is collected in secondary care

The Systemic
Anti-Cancer
Therapy (SACT)
Dataset

High Cost Drugs
(HCD) Dataset

The
Commissioning
Data Sets (CDS)
(non-medicine)

2019
ePMA Proof of
Concept to collect
ePMA data


Making prescribing
safer for patients



Providing more evidence of
the effectiveness of medicines at
treating specific illnesses



Why are we trying to collect ePMA data – COVID Collection



Why are we trying to collect ePMA data – Benefits to the NHS

First Do No Harm - The report of the Independent Medicines and Medical Devices Safety Review

Overprescribing report – good for you, good for us, good for everybody

World Health Organisation
Medication Without harm

UK 5-year action plan for antimicrobial resistance 2019 to 2024

NHS Long Term Plan
Deliver value from the £16 billion we spend on medicines

Providing information that informs safety, effectiveness, planning and policy

- Effectiveness of medicines e.g. for COVID-19
- Identification of vulnerable patients at risk from COVID-19
- Research for primary care applied to secondary care e.g. the number of new prescriptions for cardiovascular medicines during the pandemic
- Supporting the analysis and monitoring of the benefit/risk profile of new medicines
- Monitoring the use of medicines in the restraint of patients
- Monitoring of antidepressants being prescribed to under 18's
- Development of a Medicines Safety Dashboard
- Analysis of patients experiencing complications or adverse effects caused by the mixture of medicines (polypharmacy)

- Assist in shaping any future ePMA standardisation

What are we proposing to collect?



Estimated 175 Trusts in England

- ✓ Acute
- ✓ Mental health
- ✓ Specialist
- ✓ Community

WEEKLY extract
of ePMA data



- ✓ Inpatient
- ✓ Discharge
- ✓ Outpatient
- ✓ Day case
- ✓ Emergency department
- ✓ Homecare

ONE - OFF
extract of
HISTORICAL
ePMA data



- ✓ Organisation information
- ✓ Patient identifiers
- ✓ Prescribed Medication
- ✓ Dosage
- ✓ Indication
- ✓ Administration information


WEEKLY ePMA
data transferred
securely via
MESH

What are we proposing to collect? – Data collection Challenges



For medicines classed as **sensitive** or **restricted** patient identifiers will be removed. NHS Digital can remove these if a Data Processing Agreement (DPA) has been signed, otherwise the identifiers must be removed by trusts before the data is transferred

REMOVAL of sensitive or restricted patient identifiers



Feedback report will be provided to secondary care providers on any data quality and dm+d mapping issues

Data Quality FEEDBACK Loop



National Data Opt-Out status checked and all identifiable data removed for patients that have opted out

National OPT-OUT applied



Data access via **Secure Data Environments**

Protecting NHS DATA

What are we proposing to collect - Consultation

Patients

The Academy of Medical Royal Colleges

Secondary Care Chief Pharmacists

Use case owners

NHS England

Secondary Care IG leads

NHS Digital data specialists

Department of Health & Social Care

Data dissemination will be limited to NHS organisations or those commissioned by NHS organisations.

ePMA system suppliers

Medicine Programme
Medicines Data Advisory Group

This policy will be regularly reviewed to ensure it meets the needs of commissioners, patients, trusts and users of the data.

What are we proposing to collect - Patient consultation findings

I'm unsure how the NHS is collecting / using patient data, I believe the public needs reassurance

Be explicit, honest, no jargon and explain what it means to the patient NOT the NHS




Having visited hospital on countless occasions over the last 7 years, I haven't ever been informed about the use of my data other than some incomprehensible legal jargon at the bottom of the form. Clinicians haven't informed me. Patients require clarity, transparency and honesty.

How do we effectively inform patients in how their data is being managed?

- Hospital website
- Leaflets
- Speaking to patients
- Posters
- Other ?

How can NHS Digital assist trusts – hospital notice developed for COVID collection

When are we proposing to collect – What trusts would need to do



Questions & Feedback – Feedback and Questions

Feedback, thoughts and questions ?



Connect with us

 @nhsdigital

 company/nhs-digital

 www.digital.nhs.uk